backNEW YORK, Oct. 20, 2016 — LMG Life Sciences has named a King & Spalding deal — the $150 million Nurix-Celgene licensing agreement — as a Collaboration Impact Deal of the Year.
King & Spalding advised Nurix, Inc. in September 2015 on a strategic collaboration with Celgene Corp. for the discovery, development and commercialization of novel drug therapies in the fields of oncology, inflammation and immunology, including the rapidly evolving field of immuno-oncology. San Francisco partner Tom Duley, who led the King & Spalding team on the deal, accepted the LMG Life Sciences award on behalf of the firm at a ceremony Sept. 14 in New York City.
The LMG Life Sciences publication bases its research on online surveys and interviews with lawyers across the United States. Its researchers also spoke to clients and leading lawyers within the industry and reviewed public information to inform their decisions.
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 900 lawyers in 18 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.